Description: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Home Page: www.merck.com
126 East Lincoln Avenue
Rahway,
NJ
07065
United States
Phone:
908 740 4000
Officers
| Name | Title |
|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & CEO |
| Ms. Caroline Litchfield | Executive VP & CFO |
| Mr. Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health |
| Mr. Sanat Chattopadhyay | Executive VP & President of Merck Manufacturing Division |
| Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories |
| Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller |
| Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer |
| Mr. Peter Dannenbaum | Vice President of Investor Relations |
| Ms. Jennifer L. Zachary J.D. | Executive VP & General Counsel |
| Ms. Cristal N. Downing | Executive VP and Chief Communications & Public Affairs Officer |
Exchange: VI
Country: AT : Austria
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 10.6157 |
|---|---|
| Trailing PE: | 21.5639 |
| Price-to-Book MRQ: | 5.8499 |
| Price-to-Sales TTM: | 3.9202 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 70000 |